Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:

NCT ID: NCT01168245 Completed - Alzheimer Disease Clinical Trials

TMS Stimulation and Cognitive Training in Alzheimer Patients

Start date: January 2010
Phase: Phase 1
Study type: Interventional

The aim of this study is to examine if combined treatment with TMS and cognitive training (CoTra) for several weeks can produce a sustained improvement in cognitive and behavioral symptomatology of mild to moderate Alzheimer's disease (AD) patients.

NCT ID: NCT01153607 Completed - Diagnostic Imaging Clinical Trials

Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers

Start date: June 2010
Phase: Phase 1
Study type: Interventional

PET (positron emission tomography) imaging with BAY1006578 for investigation of diagnostic potential in probable Alzheimer Disease patients versus healthy volunteers and radiation dosimetry in healthy volunteers.

NCT ID: NCT01148498 Completed - Alzheimer's Disease Clinical Trials

A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

Start date: August 2010
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to compare the average change in the amount of amyloid beta species in blood after an infusion of solanezumab.

NCT ID: NCT01142336 Completed - Alzheimer's Disease Clinical Trials

Effects of Simvastatin on Biomarkers

SimBio
Start date: June 2010
Phase: N/A
Study type: Interventional

A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's disease.

NCT ID: NCT01142258 Completed - Alzheimer's Disease Clinical Trials

Trazodone for Sleep Disorders in Alzheimer's Disease

Start date: March 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether trazodone is effective in the treatment of sleep disorders in Alzheimer's disease (AD).

NCT ID: NCT01138111 Completed - Alzheimer Disease Clinical Trials

Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The aim of the study is to investigate whether Florbetaben (BAY94-9172)positron emission tomography (PET) is able to distinguish between subjects with mild cognitive impairment (MCI) progressing to Alzheimer's disease (AD) from those with MCI not progressing to AD.

NCT ID: NCT01137526 Completed - Alzheimer's Disease Clinical Trials

Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test if the investigational medication, ABT-384, is a safe and effective treatment for adults with mild-to-moderate Alzheimer's Disease.

NCT ID: NCT01133405 Completed - Alzheimer's Disease Clinical Trials

A Safety Study of LY2886721 Single Doses in Healthy Subjects

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 single doses, how the body handles the drug, and the drug's effect on the body.

NCT ID: NCT01129596 Completed - Alzheimer's Disease Clinical Trials

Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-

Start date: June 10, 2010
Phase:
Study type: Observational

The purpose of this study is to investigate the following about donepezil hydrochloride administration in patients with mild or moderate Alzheimer's Disease in clinical practice: cognitive function, Functional Assessment Staging (FAST) score, adverse events/adverse drug reactions, and patient background.

NCT ID: NCT01129115 Completed - Alzheimer's Disease Clinical Trials

Dose Response Study of Aerobic Exercise in Older Adults

Start date: May 2010
Phase: Phase 0
Study type: Interventional

This is a randomized, 26-week study of supervised exercise assessing three doses of exercise in sedentary individuals 65 years of age and over with age-related cognitive changes. A total of 100 subjects (n=25 in each of four groups) will be randomized to a non-aerobic control group, 75 minutes, 150 minutes, or 225 minutes a week of moderate intensity aerobic exercise spread over 3 to 5 days a week for 26 weeks. These exercise doses represent 50%, 100%, or 150% of the recommended exercise dose. Participants will be directly supervised during all exercise sessions for the first two months after which direct supervision will occur during at least one session a week. This is intended to provide increased flexibility while also maintaining direct contact with the participant to enhance adherence. Aerobic fitness, physical function, and cognition will be assessed at baseline and 26 weeks to examine the dose-response relationships.